SMi are pleased to announce its second annual Orphan Drugs & Rare Diseases conference due to meet on the 14 & 15 October 2013, in London. Recent years have been a time of huge growth in orphan drug development, but also a time of increased pressure as many leading blockbuster drugs soon come off patent. SMi’s orphan drugs conference will allow a specific focus on the current rare diseases drug development landscape, and where recent research will be touching upon going into the future.
Join the world leading expert speaking faculty and gain a wide ranging, highly inclusive view on the orphan drug industry as it currently stands. Speakers will highlight cutting edge research via case studies taking place in previously untreatable patients. Current regulatory policies involving the FDA & EMA, new drug discoveries and partnerships in clinical trials and drug development with patient groups.
A ‘big pharma spotlight session’ will be held on the morning of the 14th highlighting where current pipelines stand and where exactly the next succesful drug will be treating rare diseases. We will also be discussing HTA and pricing issues that are currently being implemented after recent reforms in Europe.